Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

@article{Mok2009GefitinibOC,
  title={Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.},
  author={Tony Shu Kam Mok and Yi-long Wu and Sumitra Thongprasert and Chih-Hsin Yang and Da-tong Chu and Nagahiro Saijo and Patrapim Sunpaweravong and Baohui Han and Benjamin Margono and Yukito Ichinose and Yutaka Nishiwaki and Yuichiro Ohe and Jin-Ji Yang and Busyamas Chewaskulyong and Haiyi Jiang and Emma L Duffield and Claire Watkins and Alison A. Armour and Masahiro Fukuoka},
  journal={The New England journal of medicine},
  year={2009},
  volume={361 10},
  pages={
          947-57
        }
}
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calculated to produce an area under the curve of… 
Gefitinib efficacy in adenocarcinoma
TLDR
The findings suggest that, whenever possible, EGFR-mutation status should be determined before initial treatment of pulmonary adenocarcinoma, and gefitinib was clearly superior to carboplatin–paclitaxel as first-line treatment for pulmonaryAdenocARCinoma.
Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
TLDR
Pre-planned subgroup analyses in Asian patients and non-smokers showed that in these subgroups gefitinib prolonged OS, and that EGFR biomarkers predicted a positive response to gef itinib, which was associated with significantly fewer haematological and neurological adverse effects than comparator chemotherapy regimens.
A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
  • D. Camidge, E. Berge, +12 authors A. Mita
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2014
TLDR
Ramucirumab in combination with paclitaxel–carboplatin resulted in a 6-month PFS rate and safety profile that compared favorably with the historical control, and an association of SNP on FGFR-2 gene with survival and response is described.
Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.
TLDR
Treatment with carboplatin plus nab-paclitaxel was found to be safe and effective for NSCLC patients with ILD, although management of hematological adverse events, such as febrile neutropenia, was required.
Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
TLDR
In this consecutive, non-randomized, series of advanced NSCLC patients, the use of IL-2 increased the efficacy of gefitinib and skin toxicity and use ofIL-2 were independently associated with improvement of survival.
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
TLDR
Gefitinib was well tolerated, was consistent with previous data and disease, and had fewer serious adverse events and fewer Common Terminology Criteria for Adverse Events grade 3 or 4 adverse events than docetaxel, and is an important valid treatment option for second-line therapy for Korean NSCLC patients.
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
  • K. Price, C. Azzoli, +8 authors V. Miller
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2010
TLDR
The 13% partial response rate observed did not meet the prespecified response threshold to pursue further study of the combination of gefitinib and everolimus, and further investigation of mammalian target-of-rapamycin inhibitors in patients with NSCLC with KRAS G12F-mutated tumors is warranted.
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
TLDR
The study confirms the superiority of gefitinib in prolonging PFS against the most active chemotherapy regimen of pemetrexed–carboplatin followed by maintenance pemetrezed in EGFR-mutated lung adenocarcinoma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
TLDR
Gefitinib has clinically antitumor activity and good tolerability in {Taiwan} patients with advanced NSCLC and very poor performance status, with a higher response rate than that seen Europe or in European heritage Americans.
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
TLDR
Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients, and these data support the use of gefit inib as a first-line therapy in this particular subgroup of patients.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
TLDR
None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
TLDR
Results from a placebo-controlled Phase III trial showed that treatment with gefitinib was not associated with a statistically significant improvement in survival in either the overall or adenocarcinoma co-primary populations, although there was marked heterogeneity in survival outcomes between patient groups.
EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer
  • H. Kimura, K. Kasahara, +17 authors S. Nakao
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2006
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
TLDR
In this prospective study, EGFR exon 19 deletion or L858R mutations in adenocarcinoma were the best predictors for longer TTF in stage IIIB/IV chemotherapy-naive NSCLC patients receiving first-line gefitinib monotherapy.
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
TLDR
Gefitinib chemotherapy in patients with advanced NSCLC harbouring EGFR mutations was highly effective, demonstrating the benefit to patients of selecting gefit inib treatment based on their EGFR mutation status.
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
  • A. Inoue, T. Suzuki, +6 authors T. Nukiwa
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity, and a subsequent randomized trial comparing gefITinib with standard chemotherapy is warranted.
...
1
2
3
4
...